Clinical Trial Update: Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of alpelisib and enzalutamide in androgen receptor and PTEN positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Piqray (alpelisib)
• Xtandi (enzalutamide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Status: COMPLETED